ethylketocyclazocine has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexaki, VI; Castanas, E; Hatzoglou, A; Kampa, M; Papakonstanti, EA; Stournaras, C | 1 |
| Bakogeorgou, E; Castanas, E; Damianaki, A; Hatzoglou, A; Kampa, M; Martin, PM | 1 |
2 other study(ies) available for ethylketocyclazocine and Prostatic Neoplasms
| Article | Year |
|---|---|
The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line.
Topics: Actin Cytoskeleton; Analgesics, Opioid; Binding Sites; Binding, Competitive; Carcinoma; Cell Division; Cell Membrane; Ethylketocyclazocine; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Male; Opioid Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Reaction Time; Receptors, Androgen; Serum Albumin, Bovine; Signal Transduction; Testosterone; Tumor Cells, Cultured | 2004 |
Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors.
Topics: Binding Sites; Caseins; Cell Division; Cell Survival; Enkephalins; Ethylketocyclazocine; Humans; Ligands; Male; Morphinans; Narcotic Antagonists; Narcotics; Prostatic Neoplasms; Receptors, Opioid; Tumor Cells, Cultured | 1997 |